UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 370

Sortiert nach

277P Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab

Annals of oncology, 2023-10, Vol.34, p.S295-S295

2023

Volltextzugriff (PDF)

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

British journal of haematology, 2019-11, Vol.187 (3), p.337-346

2019

Volltextzugriff (PDF)

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Clinical cancer research, 2019-11, Vol.25 (22), p.6606-6613

2019

Volltextzugriff (PDF)

Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry

British journal of haematology, 2023-02, Vol.200 (4), p.451-461

2023

Volltextzugriff (PDF)

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Haematologica (Roma), 2016-07, Vol.101 (7), p.e280

2016

Volltextzugriff (PDF)

Interstitial lung diseases in a lung cancer screening trial

The European respiratory journal, 2011-08, Vol.38 (2), p.392-400

2011

Volltextzugriff (PDF)

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.849-858

2015

Volltextzugriff (PDF)

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34 - and immature CD34 + cells

Scientific reports, 2021-03, Vol.11 (1), p.6187-6187, Article 6187

2021

Volltextzugriff (PDF)

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS

HemaSphere, 2022-06, Vol.6, p.69-70

2022

Volltextzugriff (PDF)

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

The New England journal of medicine, 2010-12, Vol.363 (26), p.2511-2521

2010

Volltextzugriff (PDF)

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia

Molecular oncology, 2018-06, Vol.12 (6), p.814-829

2018

Volltextzugriff (PDF)

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

Oncotarget, 2016-06, Vol.7 (23), p.35293-35301

2016

Volltextzugriff (PDF)

Assessment of coronary artery disease by cardiac computed tomography : A scientific statement from the american heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging, council on clinical cardiology

Circulation (New York, N.Y.), 2006-10, Vol.114 (16), p.1761-1791

2006

Volltextzugriff (PDF)

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

The New England journal of medicine, 2017-03, Vol.376 (10), p.917-927

2017

Volltextzugriff (PDF)

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

Leukemia, 2012-05, Vol.26 (5), p.1137-1140

2012

Volltextzugriff (PDF)

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

The New England journal of medicine, 2013-11, Vol.369 (19), p.1783-1796

2013

Volltextzugriff (PDF)

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia

Cancers, 2022-09, Vol.14 (19), p.4695

2022

Volltextzugriff (PDF)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Leukemia, 2020-08, Vol.34 (8), p.2125-2137

2020

Volltextzugriff (PDF)

1 – 25 von 370

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(287)
Mit Volltextzugriff
(295)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

277P Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Interstitial lung diseases in a lung cancer screening trial

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34 - and immature CD34 + cells

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Suchergebnisse filtern